


-222-

We claim:

1. A compound of Formula I



wherein:

$R^1$  is  $C_6H_5CH_2OCH_2-$ ,  $C_6H_5(CH_2)_3-$  or indol-3-ylmethyl;

Y is pyrrolidinyl, 4-methyl piperidinyl or  $NR_2R_2$ ;

$R_2$  are each independently a  $C_1$  to  $C_6$  alkyl;

$R_3$  is 2-naphthyl or phenyl para-substituted by W;

W is H, F,  $CF_3$ ,  $C_1$ - $C_6$  alkoxy or phenyl; and

$R_4$  is H or  $CH_3$ ,

or a pharmaceutically salt or solvate thereof.

2. A compound of Claim 1 wherein  $R^4$  is  $CH_3$ .
3. A compound of Claim 1 wherein said compound has the (R,R) stereo configuration.
4. A method for increasing the level of endogenous growth hormone in a human or an animal which comprises administering to said human or animal an effective amount of a compound of Claim 1.
5. A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises

-223-

administering to an animal in need of said treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

- 5 6. A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

10

7. A pharmaceutical formulation according to Claim 6 which further comprises a bone-antiresorptive agent.

15

8. A method according to Claim 7 which further comprises administering to a patient a bone antiresorptive agent.

9. A method according to Claim 8 wherein said bone antiresorptive agent is a bisphosphonate.

T05270" E9T0990